Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is March 23, 2026, covering a share repurchase executed on March 20, 2026. The transaction was conducted by BNP Paribas SA acting as a broker under a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback event rather than providing comprehensive financial statements (revenue, profit, or cash flow are not included in this document).
- Shares Purchased: 560,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,940.50p; highest price paid was 1,967.50p.
- Volume-Weighted Average Price (VWAP): 1,953.58p.
- Trading Venues: Purchases were executed across BATE, CHIX, and XLON (London Stock Exchange).
- Treasury Share Holdings: Following this purchase, GSK holds 253,222,615 ordinary shares in treasury.
- Shares in Issue: 4,062,953,663 ordinary shares (excluding treasury shares).
- Treasury Voting Rights: Treasury shares represent 6.23% of the total voting rights.
Material Changes and Program Progress
This purchase is part of GSK's existing buyback programme. Since the programme's announcement on February 17, 2026, the company has purchased a total of 13,331,521 ordinary shares. The filing confirms the reduction of shares in issue and the corresponding increase in treasury holdings, which do not carry voting rights.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, operational outlook, or management commentary regarding business performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025.
Key Facts for Investor Verification
- Verify the total number of shares purchased under the buyback programme since February 17, 2026 (13,331,521 shares).
- Confirm the updated treasury share count (253,222,615) and its impact on the total voting rights denominator (4,062,953,663).
- Note that the VWAP of 1,953.58p reflects the execution price for the 560,000 shares purchased on March 20, 2026.
- Review the "Risk Factors" in the 2025 Form 20-F for context on the buyback programme's strategic intent and potential risks.